Last reviewed · How we verify
NCT06942104
Imaging of Solid Tumors Using 18F-TRX
Phase 1 trial testing 18F-TRX in Solid Tumor in 56 participants. Currently enrolling.
30 September 2026
Quick facts
| Lead sponsor | Rahul Aggarwal |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 56 |
| Start date | 3 July 2025 |
| Primary completion | 30 September 2026 |
| Estimated completion | 30 September 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- 18F-TRX — full drug profile →
- Positron Emission Tomography (PET)/Computerized tomography (CT)
- Tumor Biopsy
- Blood Specimen Collection
Conditions studied
- Solid Tumor — all drugs for Solid Tumor →
- Solid Carcinoma — all drugs for Solid Carcinoma →
- Castration-Resistant Prostate Carcinoma — all drugs for Castration-Resistant Prostate Carcinoma →
- Locally Advanced Clear Cell Renal Cell Carcinoma — all drugs for Locally Advanced Clear Cell Renal Cell Carcinoma →
Sponsor
Rahul Aggarwal — full company profile →
Who can join
18 and older, any sex, with Solid Tumor or Solid Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase I trial tests the safety and effectiveness of 18F-TRX in detecting tumors (cancer) patients with solid tumors. 18F-TRX is an imaging tracer that is used to visualize tumors using a PET scan. It specifically targets and detects labile (unstable) iron levels within tissues, including tumors. Diagnostic procedures, such as 18F-TRX PET/CT or PET/MRI, may help detect tumors in patients with solid tumors
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06942104
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Solid Tumor
Currently open trials in the same condition.
- NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
- NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
- NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting
Other Rahul Aggarwal trials
Trials by the same sponsor.
- NCT05888532 — 64Cu-GRIP B in Patients With Advanced Malignancies · Phase 1, PHASE2 · recruiting
- NCT04926181 — Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer · Phase 2 · terminated
- NCT05011188 — FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer · Phase 1, PHASE2 · active not recruiting
- NCT04927663 — 11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression · Phase 1 · terminated
- NCT04471974 — ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer · Phase 2 · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06942104 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Rahul Aggarwal
- Last refreshed: 18 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06942104.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing